LONG-TERM SAFETY OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS

Silvio Danese  ¹     Bruce A. C. Cree  ²     Douglas C. Wolf  ³     OLGA ALEKSEEVA  ⁴     Lorna Charles  ⁵     AnnKatrin Petersen  ⁵     James K. Sheffield  ⁵     Chun-Yen Cheng  ⁵     Jon V. Riolo  ⁵     Diego Silva  ⁵     Fred D. Lublin  ⁶     Jeffrey A. Cohen  ⁷     David T. Rubin  ^8    
1 Humanitas University, Milan, Italy
² Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, United States
³ Atlanta Gastroenterology Associates LLC, Atlanta, United States
⁴ Nizhny Novgorod Regional Clinical Hospital, Nizhniy Novgorod, Russian Federation
⁵ Bristol Myers Squibb, Princeton, United States
⁶ Mount Sinai Medical Center, New York, United States
⁷ Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, United States
⁸ University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States

Topic
IBD

Session
Meet the giants at the poster (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)